REGISTRATION IS OPEN FOR THE APCCC 2026! https://nitter.cf/t.co/2VdupNgpMM APCCC facilitates discussions and debates on advanced prostate cancer diagnostic and treatment options.
Bellinzona, Switzerland
Joined November 2013
- Tweets11.2K
- Following692
- Followers5.2K
- Likes5.7K
Pinned Tweet
‼️ On 134 key questions in prostate cancer care, experts reached consensus on just 44.
What does that tell us about the evidence guiding treatment — and where do we need better answers?
📄 Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference
🔗 sciencedirect.com/science/ar…
At #APCCC26, 144 international experts 🌐 tackled challenging clinical questions where high-level evidence remains limited.
Using a modified Delphi process, 133 panellists voted on 134 questions covering high-risk localised, locally advanced and biochemically recurrent prostate cancer, including PSA persistence, PSA recurrence and treatment-related side effects.
✅ Consensus (≥75% agreement) was reached on just 44 questions (32.8%), with strong consensus (≥90%) on only seven.
👉 Where experts disagree, the need for better evidence is clear. Areas without consensus highlight important priorities for future clinical trials.
@Silke_Gillessen, @AOmlin, @Prof_Nick_James, @LVM_Walz, @AOmlin, @AttardLab, @bjartell, @LoebStacy, @Tilki_De, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @VedangMurthy, @neerajaiims, @Achard_Verane, @PBlanchardMD, @lisahorvath73, @BarbaraJereczek, @fontev1, @ChrisSweens1, @AarmstrongDuke, @CharlesRyanMD, @ProfKHerrmann, @KarimFizazi, @NealShore, @himishabeltran, @HeatherChengMD, @DrRanaMcKay, @AliciaMorgansMD, @declangmurphy, @DrSpratticus, @EvanYuMD, @NehaVapiwalaMD, @drjefstathiou, @BertrandTOMBAL @OncoAlert 🚨
#ProstateCancer #APCCC26
🚨 FDA approves talazoparib + enzalutamide for mAPMN/S prostate cancer with HRR mutations.TALAPRO-3: rPFS HR 0.48 (p<0.0001), median rPFS not reached vs 45.8 mo.
#ProstateCancer
🚨 FDA NEWS | By colleagues, for colleagues
Talazoparib + enzalutamide now approved for mAPMN/S prostate cancer with HRR gene mutations.TALAPRO-3 delivered a clear rPFS benefit (HR 0.48).
Full details & Key Facts graphic below.#OncoAlert #ProstateCancer #FDA
fda.gov/drugs/resources-info…
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
COME JOIN US in Lugano!!
#LPCCC26 coming in Late April, Submit your abstracts NOW 👉 apccc.org/call-for-abstracts
Dear GU colleagues at #ESMO26!
Dr Silke Gillessen & Dr. Aurelius Omlin🇨🇭 invite you to the inaugural LPCCC – Localised Prostate Cancer Consensus Conference!
🔬 CALL FOR ABSTRACTS NOW OPEN!
👉 Submit your abstract: apccc.org/call-for-abstracts
📅 LPCCC 2027 | 29 April – 1 May 2027
We invite colleagues in #ProstateCancer to submit their abstracts and contribute to shaping the discussion on the diagnosis and clinical management of men with localised prostate cancer.
LPCCC marks an exciting new chapter for the APCCC family, extending the consensus-conference concept to localised disease, with a particular focus on areas where evidence, guidelines and clinical practice leave important questions unanswered.
Two days of high-level presentations, expert discussion and debate will bring together the latest evidence and perspectives to address the questions that matter most in everyday clinical practice.
We look forward to your contributions!
#LPCCC27 #ProstateCancer #ESMO26
@APCCC_Lugano @BertrandTOMBAL @ChrisSweens1 @jmmrad @drjefstathiou @CaPsurvivorship @LoebStacy @charlesryanmd @AarmstrongDuke @Ecastromarcos @LVM_Walz @piet_ost @Nicola_Fossati @AnthonyMJoshua @Prof_Nick_James @VedangMurthy @AttardLab @Silke_Gillessen @AOmlin @ProfKHerrmann
📣 Also tagging: @AmandaNizamMD @scocmem @nataliagandur @gu_onc @tompowles1 @brian_rini @declangmurphy @cdanicas @neerajaiims
A warm welcome to all of our Colleagues to Lugano🇨🇭
for #LPCCC27 in #ProstateCancer
Best,
@Silke_Gillessen @ProfKHerrmann @AOmlin & Jochen Walz
Dear GU colleagues at #ESMO26!
Dr. Silke Gillessen 🇨🇭invites you to the inaugural LPCCC – Localised Prostate Cancer Consensus Conference!
🔬 CALL FOR ABSTRACTS NOW OPEN!
👉 Submit your abstract: apccc.org/call-for-abstracts
📅 LPCCC 2027 | 29 April – 1 May 2027
We invite our colleagues in #ProstateCancer to submit their abstracts and contribute to shaping the discussion on the diagnosis and clinical management of men with localised prostate cancer.
LPCCC marks an exciting evolution of the APCCC family, extending the consensus-conference concept to localised disease, with a particular focus on areas where evidence, guidelines and clinical practice leave important questions unanswered.
Two days of high-level presentations, discussion and debate will bring together the latest evidence and expert perspectives to address the questions that matter most in everyday clinical practice.
We look forward to your contributions!
#LPCCC27 #ProstateCancer #ASTRO26
@APCCC_Lugano, @BertrandTOMBAL, @ChrisSweens1, @jmmrad, @drjefstathiou, @CaPsurvivorship, @LoebStacy, @charlesryanmd, @AarmstrongDuke, @Ecastromarcos, @LVM_Walz, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @Prof_Nick_James, @VedangMurthy, @AttardLab, @Silke_Gillessen, @AOmlin, @ProfKHerrmann
Pinging @AmandaNizamMD, @scocmem, @nataliagandur, @gu_onc, @tompowles1, @brian_rini, @declangmurphy, @cdanicas, @neerajaiims
JOIN US IN LUGANO 🇨🇭for #LPCCC26
This quoted post is unavailable.
Looking forward to this presentations at #ESMO26
Long-Term Overall Survival With Abiraterone Acetate Plus Prednisone in the PEACE-1 Phase 3 Trial for De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Long-Term Overall Survival With Abiraterone Acetate Plus Prednisone in the PEACE-1 Phase 3 Trial for De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
@RayMcDermott1
@BertrandTOMBAL
🔬 Phase 3, 2×2 factorial (n=1173): abiraterone and/or prostate RT added to SOC (ADT ± docetaxel) in de novo mCSPC. Median follow-up 7.7 y.
➡️ Abiraterone: OS HR 0.75 (0.65–0.87); p=0.0001
➡️ ADT + docetaxel ± abiraterone: median OS 4.4 vs 6.2 y; 8-year OS 27.1% vs 40.3%
➡️ High-volume: 8-year OS 20% vs 38%; interaction by metastatic extent p=0.56
✅ Major OS benefit of adding abiraterone to SOC, irrespective of metastatic extent; triplet associated with almost twice as many long-term survivors in some subgroups.
#ProstateCancer
🎙️ Karim Fizazi
👥 Stéphanie Foulon · Joan Carles · Guilhem Roubaud · Ray McDermott · Aude Fléchon · Bertrand Tombal · Stéphane Supiot · Dominik Berthold · Philippe Ronchin · Gabriel Kacso · Gwenaëlle Gravis · Fabio Calabro · Jean-François Berdah · Ali Hasbini · Marlon Silva · Antoine Thiery-Vuillemin · Igor Latorzeff · Loïc Mourey · Brigitte Laguerre · Sophie Abadie-Lacourtoisie · Etienne Martin · Claude El Kouri · Anne Escande · Alvar Rosello · Nicolas Magne · Friederike Schlurmann · Frank Priou · Marie-Eve Chand-Fouche · Salvador Villà Freixa · Muhammad Jamaluddin · Isabelle Rieger · Alberto Bossi
(4Sight Made from Abstracts publicly available at the ESMO website)
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper
Can three routine blood tests improve risk stratification in advanced prostate cancer?
ascopubs.org/doi/10.1200/CCI…
Development and External Validation of a Machine Learning-Derived Risk Stratification Score for Metastatic Castration-Resistant Prostate Cancer
PROGRESS is a machine learning-informed prognostic score developed to improve risk stratification in metastatic castration-resistant #ProstateCancer (mCRPC).
➡️Combining three routine laboratory measures—PSA, alkaline phosphatase, and AST—the tool consistently distinguished patients with different overall survival outcomes across independent validation cohorts.
➡️ Its simplicity and reproducibility may support clinical decision-making and trial enrichment, although prospective real-world validation remains necessary before widespread implementation in clinical practice.
@LauraCastr83928, @xcraz_1, @josecastillocal
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
🧬 Could a tumor’s androgen receptor mutation determine whether a novel prostate cancer therapy works?
ascopubs.org/doi/10.1200/JCO…
Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer
Bavdegalutamide (ARV-110), an oral PROTAC androgen receptor degrader, demonstrated manageable safety and promising activity in metastatic castration-resistant #ProstateCancer (mCRPC).
➡️In this phase I/II study, responses were particularly notable in tumors harboring AR T878/H875 mutations, with a 60% PSA50 response rate and median radiographic progression-free survival of 11.1 months.
✅These findings highlight the potential of molecularly guided treatment and targeted protein degradation in advanced prostate cancer, warranting further clinical investigation.
@BGarmezy, @ArashRezazadeh6, @DanielPetrylak, @cnsternberg, @sartor_oliver, @maughanonc, @johnshenmd
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Can repeated metastasis-directed radiotherapy ☢️delay ADT in oligorecurrent prostate cancer—and which patients benefit most?
thegreenjournal.com/article/…
Repeated metastasis-directed radiotherapy in patients with oligorecurrent prostate cancer: outcomes and risk stratification from a large multinational PSMA PET-guided cohort
Repeated metastasis-directed radiotherapy (MDRT) may help selected patients with oligorecurrent #ProstateCancer delay androgen deprivation therapy (ADT).
➡️ In this 177-patient multinational cohort, 50.2% remained ADT-free two years after their second MDRT cycle.
➡️Longer intervals between treatments and fewer new metastases independently predicted longer ADT-free survival. While promising, the absence of a comparator group highlights the need for prospective studies to clarify treatment benefit and optimise patient selection.
@GiulioFrancoli1
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
🔬 Can genomic classifiers help us personalise salvage treatment for recurrent prostate cancer after radiotherapy?
ascopubs.org/doi/10.1200/JCO…
Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial
The F-SHARP phase I/II trial evaluated dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) for intraprostatic radiorecurrence following prostate radiotherapy☢️
➡️Among 62 patients, treatment demonstrated a favourable safety profile, with no acute grade 3 toxicities and 3.2% late grade 3 toxicity.
✅Three-year metastasis-free survival reached 85.9%. Higher genomic classifier scores correlated with poorer outcomes, highlighting their potential to identify patients who may benefit from treatment intensification. Further validation is needed. #ProstateCancer
@abhiasolanki
@ndesai2005
@DrMikeFolkert
@gupta_go
@TimShowalter1
@SteveKregel
@MattHarkenrider
@Davicioni
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Great science coming to #ESMO26 🔬
We’re looking forward to the #ProstateCancer presentations in Madrid 🇪🇸
The OncoAlert🚨 Top 10 in GU cancer is out, with contributions from our own @Silke_Gillessen 🇨🇭 and @AOmlin 🇨🇭
🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯
#BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866
#ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS
#KidneyCancer: LITESPARK-011 & -012, ivonescimab, PE-PE, SWOG S2200, XmAb819
Our Participating Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger , @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi , @AmandaNizamMD, @drenriquegrande, @nataliagandur
@AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun , @ravikanesvaran , @BraunMDPhD, @EfstathiouEleni, @mzugman , @crisbergerot, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas , @sonpavde , @Dr_Oncologista
🧬 Could the first treatment cycle reveal how long a prostate cancer patient may benefit from therapy?
jamanetwork.com/journals/jam…
Mathematical Biomarkers of Adaptive Therapy Outcomes in Prostate Cancer
This modeling study of 53 patients across two clinical trials found that mathematical biomarkers derived from initial PSA dynamics predicted progression and overall survival in #ProstateCancer patients receiving adaptive hormone therapy.
➡️Unlike conventional PSA 🧪measures, these mechanism-based biomarkers 🎯captured tumor sensitivity and resistance dynamics, offering a promising, noninvasive approach to personalizing treatment schedules.
➡️Although retrospective and based on small cohorts, the findings support further prospective validation to advance individualized, evolution-informed cancer care.
@SciKit_G, @StroblMAR, @ara_anderson, @PhilipMaini, @MoffittNews, @mathonco
@Oncoalert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Call For Abstracts
📢 Only one month left!
The countdown is on: just 30 days left to submit your abstract for #LPCCC2027!
Don't miss the opportunity to share your research, innovations, and experiences with the community. Submit your abstract before the deadline!
📅 Submission deadline: 14 November 2026
Categories:
· Localised Prostate Cancer
· Locally Advanced Prostate Cancer
· Biochemical Recurrence (BCR)
· Diagnostics and Detection of Localised Prostate Cancer
· Quality of Life / Patient-Reported Outcomes
Win a complimentary Registration!
LPCCC is pleased to offer one complimentary registration to the presenting author of each of the 10 best abstracts. The winners will be announced with the notification at the end of December.
⏳ Submit your abstract today and contribute to the discussion at #LPCCC2027.
onlineevent.ch/LPCCC/abstrac…
Events Details:
📍 Palazzo Congressi, Lugano, Switzerland
🎟️ Register here: onlineevent.ch/LPCCC/2027
🎓 Credits requests: EACCME, SGU – SSU, SSMO, SRO, SGMN
@ProfKHerrmann & Jochen Walz
@Silke_Gillessen & @AOmlin
@OncoAlert
🧬 Can combining targeted therapies improve prostate cancer outcomes—or are we adding toxicity without enough clinical benefit?
nature.com/articles/s41591-0…
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
A randomized phase 2 trial evaluated talazoparib plus enzalutamide 🆚 enzalutamide 💊 alone in high-volume metastatic hormone-naive #ProstateCancer
➡️ Although combination therapy achieved a 73% PSA response rate at 12 months, superiority over monotherapy was not established.
➡️ Grade ≥3 adverse events were more frequent with combination treatment, including two fatal myeloid neoplasms.
✅ Tumor analyses revealed androgen receptor inhibition altered gene expression without impairing functional homologous recombination, highlighting challenges in identifying patients most likely to benefit.
@FrancescaZacc14, @Ecastromarcos, @AlejoRodrguezV1, @begona_mellado, @cdanicas, @BorqueFernando, @Jacquesplanas, @Dav_Lorente, @julianbrandariz, @_NicoAnse, @AnaVivancosVHIO, @PaoloNuciforo, @eportacangen, @quimmateo
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
🧬 Can we target cancer by degrading the driver—not just inhibiting it?
ascopubs.org/doi/10.1200/JCO…
Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer
Bavdegalutamide (ARV-110), an androgen receptor–targeting PROTAC degrader, demonstrated promising activity in metastatic castration-resistant #ProstateCancer (mCRPC) following androgen receptor pathway inhibitor treatment.
➡️ In this phase I/II study, responses were strongest among patients with AR T878/H875 mutations, achieving a 60% PSA50 response rate and median radiographic progression-free survival of 11.1 months.
➡️ Toxicity was manageable, with no grade 4 or higher treatment-related adverse events, supporting further biomarker-driven investigation.
@jpshen_md, @sartor_oliver, @cnsternberg, @BGarmezy, @maughanonc, @ArashRezazadeh6, @DanielPetrylak
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@Silke_Gillessen
Are we underestimating aggressive prostate cancer by missing its most important histological warning signs?
nature.com/articles/s41585-0…
Cribiform and intraductal carcinoma in prostate cancer-implications for risk stratification and therapeutic decision making (REVIEW)
Intraductal carcinoma of the prostate (IDC) 🔬 and invasive cribriform carcinoma are aggressive histological patterns associated with adverse pathology, metastasis, and prostate cancer mortality.
➡️ Frequently underdetected on biopsy, they exhibit PTEN loss, genomic instability, DNA-repair alterations, and immunologically cold tumour microenvironments.
➡️ Although these features suggest potential biomarker-directed therapies, evidence remains insufficient.
✅ Standardized reporting, improved detection, and prospective studies are essential to guide risk stratification and treatment decisions. #ProstateCancer
@ruimmbernardino, @JoaoPedroLobo89, @ZSchwen, @Adam_Weiner535, @JaneNguyen44, @NicolasSoputro, @GhandourRashed, @TunaBeksac, @KarimDaherMD, @roodvdb, @GMarra_MD, @FalzarsMd, @DrCristinaMagi, @cosimodenunzio, @FleshnerNeil, @Dr_JihadKaouk, @ricautor
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
🧬 Can we more than double progression-free survival in oligorecurrent hormone-sensitive prostate cancer by combining targeted radioligand therapy with SBRT?
ascopubs.org/doi/10.1200/JCO…
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy ☢️ for Oligorecurrent Prostate Cancer (LUNAR)
The phase II LUNAR 🌜trial investigated whether adding PSMA-targeted radioligand therapy (¹⁷⁷Lu-PNT2002) before stereotactic body radiotherapy (SBRT) improves outcomes in oligorecurrent hormone-sensitive prostate cancer. Among 92 randomized patients, combination therapy significantly prolonged median progression-free survival from 7.4 to 17.6 months.
@AmarUKishan, @CalaisJeremie, @theboutroslab, @wayne_brisbane, @JoanneWeidhaas, @kristenmcgreevy, @SophiaParmisano
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
We are LIVE from #FlorenceConsensus26 🇮🇹 and Proud to have our amazing @Silke_Gillessen 🇨🇭giving a great Keynote lecture on a glance into the future of treatment in metastatic Hormone Sensitive #ProstateCancer
@OncoAlert 🚨
@BertrandTOMBAL, @ChrisSweens1, @CaPsurvivorship, @LoebStacy, @charlesryanmd, @AarmstrongDuke, @Ecastromarcos, @LVM_Walz, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @Prof_Nick_James, @VedangMurthy, @AttardLab, @Silke_Gillessen, @AOmlin, @ProfKHerrmann, @AmandaNizamMD, @scocmem, @nataliagandur, @gu_onc, @tompowles1, @brian_rini, @declangmurphy, @cdanicas, @neerajaiims, @RobClarkeLab, @ALEDIGNUS12, @ClareIsacke, @matteolambe, @Icro_Meattini, @MassimoDiMaio75, @DrRanaMcKay, @alison_tree, @ChadTangMD, @DrYukselUrun, @DrDanielHeng
🎯 Can we achieve excellent prostate cancer control without compromising long-term tolerability?
brachyjournal.com/article/S1…
Safety and early outcomes of external beam radiation therapy with low dose brachytherapy boost in patients with prostate cancer: A single institution experience
A retrospective study of 307 patients evaluated external beam radiation therapy (EBRT) ☢️ combined with a low-dose-rate brachytherapy boost for intermediate- and high-risk #ProstateCancer .
➡️At 4.6 years’ median follow-up, five-year biochemical recurrence-free survival reached 98% for intermediate-risk and 90% for high/very high-risk disease.
➡️ Grade ≥3 late genitourinary or gastrointestinal toxicity occurred in 3.2%, supporting the approach as a treatment option for appropriately selected patients in routine clinical practice.
@ChadTangMD
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
